首页> Vaccine> Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.

Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.

导出原文传递

翻译打印收藏纠错

第一作者： A T,Newall

第一单位： School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia. Electronic address: a.newall@unsw.edu.au.

作者： A T,Newall ^[1] ; J G,Wood ^[2] ; C,Chen ^[2] ; P,McIntyre ^[3] ; P,Beutels ^[4]

作者单位： School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia. Electronic address: a.newall@unsw.edu.au. ^[1] School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia. ^[2] National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), Kids Research Institute, Children's Hospital at Westmead, NSW, Australia. ^[3] School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia; Centre for Health Economics Research and Modelling Infectious Diseases (CHERM ID), Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium. ^[4]

关键词 Adult vaccination Economic evaluation Elderly PPV23 Pneumococcal Pneumonia

医学主题词澳大利亚(Australia);费用效益分析(Cost-Benefit Analysis);人类(Humans);肺炎球菌感染(Pneumococcal Infections);多糖类(Polysaccharides);回顾性研究(Retrospective Studies);接种(Vaccination)

DOI 10.1016/j.vaccine.2019.09.108

PMID 31733945

发布时间 2020-06-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交